Table 2.
Cardiovascular Outcomes at 3 Years
| Clinical outcome | Atorvastatin (n = 1349) | Rosuvastatin (n = 872) | P-value |
|---|---|---|---|
| New onset diabetes mellitus | 99 (7.5) | 70 (9.2) | 0.550 |
| MACE | 149 (11.0) | 91 (10.4) | 0.662 |
| All cause of mortality | 49 (3.6) | 25 (2.9) | 0.335 |
| Cardiac death | 19 (1.4) | 14 (1.6) | 0.710 |
| Non-cardiac death | 30 (2.2) | 11 (1.3) | 0.103 |
| Any myocardial infarction | 30 (2.3) | 15 (1.8) | 0.409 |
| STEMI | 8 (0.6) | 1 (0.1) | 0.083 |
| NSTEMI | 22 (1.7) | 14 (1.6) | 0.956 |
| Any revascularization | 98 (7.4) | 62 (7.2) | 0.892 |
| TLR | 24 (1.9) | 21 (2.5) | 0.312 |
| TVR | 48 (3.7) | 34 (4.0) | 0.692 |
| NTVR | 51 (3.9) | 31 (3.7) | 0.788 |
| Stroke | 27 (2.0) | 10 (1.2) | 0.127 |
MACE major adverse cardiovascular event, STEMI ST-segment elevation myocardial infarction, NSTEMI Non-ST-segment elevation myocardial infarction, NTVR non-target vessel revascularization, TLR target lesion revascularization, TVR target vessel revascularization